Better Growth Stock: Novo Nordisk vs. Pfizer
Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID revenue diminishes. Novo Nordisk's strategy centers around a fast-growing product in Wegovy. The business isn't as diverse as Pfizer's, but the upside Wegovy possesses could make up for that. Which of these stocks should growth investors buy today?
Pfizer has been raking in the profits and free cash flow from its COVID-19 vaccine and pill. Even though that likely won't be a source of growth for the business moving forward, the company can still reap the rewards. As of July 2, Pfizer had cash and investments totaling nearly $45 billion.
With plenty of resources to tap into, the company is in a great position to invest in its future growth. And Pfizer has already been busy with acquisitions in recent years, including the following deals:
Source Fool.com
Pfizer Inc. Aktie
Deutliches Buy-Überwiegen bei Pfizer Inc. im Vergleich zu Sell-Einschätzungen.
Für Pfizer Inc. ergibt sich mit einem Kursziel von 41 € eine mögliche Steigerung von über 50% gegenüber 26.96 €.
